


## PHARMACEUTICAL 2023




## Cyclerion Therapeutics Inc. Rank 391 of 446





## PHARMACEUTICAL 2023





The relative strengths and weaknesses of Cyclerion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cyclerion Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 18% points. The greatest weakness of Cyclerion Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 214% points.

The company's Economic Capital Ratio, given in the ranking table, is -203%, being 246% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	14,820
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,627
Liabilities, Non-Current	0
Other Assets	3,259
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	294
Other Revenues	1,625
Property and Equipment	0
Research and Development	31,493
Selling, General and Administrative Expense	14,504

Output Variable	Value in 1000 USD
Assets	18,079
Liabilities	7,627
Expenses	45,997
Revenues	1,625
Stockholders Equity	10,452
Net Income	-44,078
Comprehensive Net Income	-44,078
Economic Capital Ratio	-203%

